Aspirin Use Tied to Lower Rates of COVID-19 Infection
Eugene Merzon, M.D., from Leumit Health Services in Tel‐Aviv, Israel, and colleagues used data from the Leumit Health Services database to assess outcomes among COVID-19-positive patients (Feb. 1, 2020, to June 30, 2020) using preinfection treatment with low-dose aspirin for primary and secondary prevention of cardiovascular diseases versus nonusers.
The researchers found that aspirin use was associated with a lower likelihood of COVID-19 infection versus nonuse (adjusted odds ratio, 0.71). While aspirin users were older, presented a lower body mass index, and showed a higher prevalence of hypertension, diabetes, and chronic obstructive pulmonary disease than aspirin nonusers, COVID-19 disease duration among aspirin users was significantly shorter versus aspirin nonusers. A higher proportion of patients surviving hospitalization were treated with aspirin, compared to the one patient who died, but this difference was not significant.
"This observation of the possible beneficial effect of low doses of aspirin on COVID-19 infection is preliminary but seems very promising," a coauthor said in a statement.
© 2021 HealthDay. All rights reserved.
Posted: March 2021
Further Support and Information on COVID-19
Read this next
Here is what the editors at Physician's Briefing chose as the most important COVID-19 developments for you and your practice for the week of April 12 to 16, 2021. This roundup...
FRIDAY, April 16, 2021 -- The United States should support efforts to temporarily waive intellectual property rules so that nations struggling to vaccinate their populations...
FRIDAY, April 16, 2021 -- The COVID-19 death toll in Europe has surpassed 1 million, and it is seeing about 1.6 million new cases each week, a top World Health Organization...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.